Novavax grants LG Life Sciences an exclusive license to influenza vaccines that use Novavax's recombinant virus-like particle (VLP) technology in South Korea and 15 emerging markets

Novavax Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

LG Life Sciences Ltd.

South Korea / Small-Cap Biopharma (<$1 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced